Intranasal Covid-19 Vaccine Booster to be Rolled Out by Feb, 15,000 Doses Reach Kasauli Lab

0

Last Updated: January 18, 2023, 10:01 IST

In December, the intranasal Covid-19 vaccine was approved by the Union Health Ministry as a booster dose for those aged 18 and above. (Twitter @PBNS_India)

In December, the intranasal Covid-19 vaccine was authorized by the Union Health Ministry as a booster dose for these aged 18 and above. (Twitter @PBNS_India)

Packed in six batches, the needle-free vaccine will be priced at Rs 800 per dose within the non-public market and Rs 325 for presidency amenities

The world’s first intranasal Covid-19 vaccine, Bharat Biotech’s iNCOVACC, is probably going to be rolled out by February, News18.com has learnt. Last week, greater than 15,000 doses reached India’s apex vaccine testing laboratory in Kasauli, Himachal Pradesh.

BBV154, a novel adenovirus vectored, intranasal vaccine for Covid-19, packed in six batches, was despatched to the Central Drugs Laboratory (CDL), Kasauli, final week. These batches are seemingly to be launched by the primary week of February.

“If everything goes well, CDL shall be reporting by first week of February and other formalities will be completed immediately before releasing the lot for public use by early February,” mentioned a authorities official privy to the event.

In December, the intranasal Covid-19 vaccine was authorized by the Union Health Ministry as a booster dose for these aged 18 and above.

“This vaccine received approval under restricted use in emergency situations for ages 18 and above for primary 2 dose schedule, homologous booster doses,” mentioned the federal government launch dated December 1.

While the vaccine has been slotted on the CoWin platform for reserving, the rollout hasn’t begun but.

Bharat Biotech has introduced that the vaccine will be priced at Rs 800 per dose within the non-public market and Rs 325 for presidency amenities.

However, it isn’t but clear if the central authorities plans to procure the intranasal vaccine for public hospitals. Till now, solely non-public hospitals in main cities have proven curiosity in shopping for the vaccine as demand for booster doses stays low.

Non-invasive, needle-free vaccine is probably going to stop an infection and transmission aside from stopping the extreme illness.

Read all of the Latest India News right here

Source hyperlink

LEAVE A REPLY

Please enter your comment!
Please enter your name here